Provider review
Alan Health Review: What Its GLP-1 Plans Actually Cost
Alan Health advertises four different GLP-1 entry prices on one banner, and the cheapest one is the shortest plan. That headline is a promotion: two months paid upfront, one of them free, against a regular $315 a month. Its twelve-month and six-month plans are both quoted higher per month than the promotion, and no renewal price is published for any of them. On the claims side, Alan is careful where it counts: it reserves the words “FDA-approved” for the four branded drugs it also sells, and states plainly on its compounded product page that compounded medicines are not.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Alan HealthOf Alan Health’s 1 dated product claim documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Prices four different GLP-1 entry rates on one banner, and the cheapest is a buy-one-get-one-free promotion on a two-month prepay rather than a standing rate. On the regulatory question it is careful: the approval claims belong to the branded drugs it sells, and its compounded page says compounded medicines are not FDA-approved.
Correction, August 2026
This review previously said: “Alan Health calls its compounded GLP-1 injections FDA-approved in six places. Its own page says they come from compounding pharmacies. Both cannot be true.”
That was wrong. Alan sells four branded, genuinely FDA-approved drugs on the same product grid as its compounded ones, and every branded card carries an "FDA Approved" badge above a description using the phrase. The three sentences this review quoted as Alan's claim about its compounded product are those branded cards' own descriptions — two belong to Wegovy and one to Mounjaro. We cannot tell you whether the copy moved after 14 August or whether the original read joined a badge to the wrong card, and either answer would be a guess. A grid that alternates approved and compounded rows is exactly where a reading like this goes wrong, and the fix is to attribute every quoted sentence to the card it sits on before publishing it.
It now says: Re-read 2026-08-25. "FDA-approved" appears ten times across the home and weight-loss pages, and every occurrence is on a Wegovy, Zepbound, Ozempic or Mounjaro card. The compounded rows read "Prescription compounded Semaglutide injections with personalized dosing" and claim no approval. The compounded product page states: "Compounded medications are not FDA-approved; results vary." On the evidence available today, Alan labels the distinction correctly, and this review no longer says otherwise. Its open FDA warning letter, which concerns the name on the pictured labels rather than any advertising copy, is unaffected and stands as recorded below.
Worth trusting if
- You want the compounded-versus-approved line drawn for you — Alan sells both and says which is which on every card
- You will prepay two months while the buy-one-get-one-free promotion runs, because that is the plan the headline rate belongs to
- You want a low entry price and will confirm the renewal rate before paying, since none is published
Be skeptical if
- You are comparing per-month rates across plan lengths — the twelve-month and six-month plans are quoted higher per month than the two-month promotion
- You want a named pharmacy or a published test result, because neither exists here
- You will not create a password-protected account, because the signup demands one at the second screen
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
February 2026
Provenance
Products reviewed at Alan Health
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded GLP-1 injection — There are four GLP-1 entry rates on one banner, not one. $158/mo is the headline, and the product page shows it against $315 struck through under "PROMOTION: Buy 1 month, get 1 month free", footnoted "Paid upfront with a 2-month plan". Beside it the same banner offers $195/mo on twelve-month plans and $215/mo on six-month plans, so the longer commitments are quoted higher per month than the promotion. No renewal rate is published for any of them. Microdosing GLP-1 starts at $125/mo paid upfront on six months, and B12/MIC at $105/mo on six.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 1 product reviewed here. The evidence concerns the molecule, not Alan Health's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Alan Health’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded GLP-1 injectionSemaglutide · Compounded (503A)Claim matches the trials
“In Stock — Personalized Compounded Semaglutide — Prescription compounded Semaglutide injections with personalized dosing. […] Compounded Semaglutide may include B6, B12, Glycine, and NAD+. […] Medication may be prescribed by a licensed provider when clinically appropriate and dispensed by a compounding pharmacy. Compounded medications are not FDA-approved; results vary. […] U.S. compounded medications from 503a and 503b pharmacies”
Read on the Alan Health site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the trial that supports the FDA-approved product, not a compounded preparation.
Alan makes no efficacy claim for its compounded semaglutide at all. The card says "Prescription compounded Semaglutide injections with personalized dosing", which is a description of what it is, not a promise about what it does, and there is no percentage, no timeline and no trial reference. The product page then prints the disclosure that matters: "Compounded medications are not FDA-approved; results vary." The words "FDA-approved" do appear across these pages, ten times between the home and weight-loss pages, and every one of them sits on a Wegovy, Zepbound, Ozempic or Mounjaro card carrying an "FDA Approved" badge — four drugs that are FDA-approved. Selling approved brands beside compounded copies on one grid puts a real burden on the labeling, and here the labeling carries it. Two things still deserve a reader's attention: the compounded preparation "may include B6, B12, Glycine, and NAD+", so it is not the molecule the phase 3 trials tested even before you get to the compounding question, and "personalized dosing" is not a regimen any registered trial has run.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. Alan says it supplies “U.S. compounded medications from 503a and 503b pharmacies” and refers to “vetted pharmacy partners” and “trusted pharmacy partners”, but identifies none, so neither regulatory category can be checked against a licensee. Naming both 503a and 503b without saying which applies to which product is itself unclear: the two are different regulatory regimes with different oversight.
Read on the Alan Health site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency result, purity result or third-party test is published or offered, and no pharmacy is named that could be asked for one. The compounded product page does carry a quality section describing a testing program — "USP-compliant sterility and endotoxin screens", "verified potency", "Testing follows current USP chapters, FDA guidance, and cGMP best practices", footnoted to USP <797> and USP <85>. That names the standards being worked to, which is more than most of this market does. It is still a description of a process rather than a result for any batch, and there is no lot number, no laboratory and no document to read.
Read on the Alan Health site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
No state list or set of exclusions is published on the public pages. Delivery is stated as three days or less from its pharmacy partners, without naming the jurisdictions served.
Read the full licensing claim
U.S. compounded medications from 503a and 503b pharmacies
Read on the Alan Health site, August 2026.
Regulatory
The FDA warning letter
Issued February 2026
Alan Health Technologies Inc. dba Alan — MARCS-CMS 721814. Concerns marketing and labeling.
Read the full allegation
FDA reviewed the website at Alan Health's website in December 2025 and cited its representations as false or misleading under FD&C Act sections 502(a) and 502(bb). The letter's single finding: "The compounded semaglutide and tirzepatide products displayed on your website identify 'Alan' on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not." It quotes no advertising copy, makes no allegation about sterility, potency, contamination or any other product-quality matter, and states its citations are "not intended to be an all-inclusive statement of violations."
We did this ourselves
What happens when you sign up with Alan Health
We went through Alan Health’s signup ourselves in August 2026: the steps, when a price first appears, and what it asks you for. We stopped at checkout, so nothing here is a prescription or a medical result.
- Pick a product from the weight-loss grid and press "Get started". Every price you will be quoted is already on the banner above it.
- The visit opens on Alan Health's health storefront and asks for an email address before anything else.
- The next screen is "Create an account" — first name, last name, and a password of at least eight characters with an uppercase letter, a number and a symbol, plus a terms and telehealth consent box.
- This walk stopped there. We do not create password-protected accounts, so nothing past that screen was seen.
- Four GLP-1 entry rates sit on one banner before any question: $158/mo, $195/mo on twelve-month plans, $215/mo on six-month plans, and $105/mo for B12/MIC on six months.
- The cheapest rung is the shortest commitment because it is a promotion: $158/mo is "Buy 1 month, get 1 month free" on a two-month prepay, against $315 a month struck through. The twelve- and six-month plans are quoted higher per month than that.
- Every advertised figure is a prepay rate. No renewal price is published for any plan, so what you pay in month three is not on the site.
- The product grid mixes four approved brands with the compounded rows, and the approved ones carry an "FDA Approved" badge. The compounded rows carry none, and the compounded product page says compounded medicines are not FDA-approved.
- The compounded semaglutide "may include B6, B12, Glycine, and NAD+", which is stated in a footnote under the ordering steps rather than on the product itself.
- The visit demands an account with a password at its second screen, before a single medical question and before any price is confirmed.
- A "Virtual consultation" is listed as step two of the advertised process: "Chat with a US-certified doctor to get your prescription."
Alan Health support
- Phone
- 855-837-6337
Assessment
What holds up, and what does not
- Its compounded product page states "Compounded medications are not FDA-approved; results vary" — the disclosure two companies in this market hold open FDA letters for omitting.
- It reserves the words "FDA-approved" for the four branded drugs it also sells, each of which is.
- The asterisk on the headline price is resolved in the same banner: "Paid upfront with a 2-month plan."
Show 4 more
- It names its regulatory categories — 503a and 503b — rather than saying only “licensed pharmacy”, which is more specific than much of this category manages.
- The operating company is named: Alan Health Technologies, Inc.
- The entry price is among the lower ones published for a compounded GLP-1.
- Delivery timing is stated concretely as three days or less.
- The headline rate is a promotion — buy one month, get one free — and the regular price beside it is struck through at double.
- Every advertised figure is an upfront prepay rate, and no renewal price is published for any plan.
- Approved brands and compounded copies sit on one grid, so the badge is doing all the work of telling them apart.
Show 6 more
- The compounded preparation "may include B6, B12, Glycine, and NAD+", which is not what the phase 3 trials tested.
- No pharmacy is named, so neither the 503a nor the 503b claim is checkable.
- It cites 503a and 503b together without saying which applies to what — they are different regimes with different oversight.
- No certificate of analysis or test result is published.
- An open FDA warning letter (721814, February 2026) found the pictured product labels implied Alan compounds the drugs itself.
- The signup demands a password-protected account at the second screen, before any medical question or any price is confirmed.
Verdict
The bottom line
Do not use this site to answer whether your medication is FDA-approved, because it gives both answers. If the product is compounded — and Alan says it is — then it has not been through FDA review, and the phase 3 evidence a reader has in mind belongs to Wegovy and Ozempic rather than to what arrives in the vial.
Opens Alan Health's website. A link is not a recommendation to take anything.
What a month costs, and which month
Alan's banner carries four GLP-1 entry prices at once, before you answer anything:
- $158/mo — the headline, footnoted "Paid upfront with a 2-month plan"
- $195/mo — "12-Month Plans Available"
- $215/mo — "6-Month Plans Available"
- $105/mo — B12/MIC, six-month plans
Read that ladder twice. In this market a longer commitment normally buys a lower monthly rate; here the twelve-month and six-month plans are both quoted above the two-month one. The product page explains why: the $158 is a promotion, "Buy 1 month, get 1 month free", shown against $315 struck through. Outside the promotion, a month is priced at double the headline.
Every one of those figures is a prepay rate. No renewal price is published for any plan, so the site does not tell you what month three costs.
Full analysis — 5 more sectionsApproved and compounded, on one grid · What is actually in the vial · What the FDA letter does and does not cover · What is not published · Where the visit stops
Approved and compounded, on one grid
Alan sells both. On the weight-loss page the rows run:
"In Stock — Personalized Compounded Semaglutide — Prescription compounded Semaglutide injections with personalized dosing."
"Limited Supply · FDA Approved — Wegovy® (semaglutide) — Manage weight with a once-weekly, FDA-approved injection."
That is the arrangement most likely to mislead a hurrying reader, and here the labeling holds up: the phrase "FDA-approved" appears ten times across the home and weight-loss pages and every occurrence belongs to Wegovy, Zepbound, Ozempic or Mounjaro, each with an "FDA Approved" badge. Those four drugs are approved. The compounded rows claim nothing of the kind, and the compounded product page prints the sentence that settles it:
"Compounded medications are not FDA-approved; results vary."
That is the disclosure two companies reviewed on this site hold open FDA letters for leaving out.
What is actually in the vial
One line in a footnote under the ordering steps is worth more attention than the badge argument:
"Compounded Semaglutide may include B6, B12, Glycine, and NAD+."
So the product is a combination preparation, not the molecule STEP 1 tested. 1 Add "personalized dosing" — a regimen no registered trial has run — and the distance between what the trials measured and what ships is larger than the compounding question alone suggests. Alan does not claim otherwise; it makes no efficacy claim for this product at all. A reader carrying the phase 3 numbers in their head should know they were not measured on this.
What the FDA letter does and does not cover
Alan Health Technologies has an open warning letter, 721814, from February 2026. Its single finding is narrow: the compounded products pictured on Alan Health's website "identify 'Alan' on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not", citing 21 CFR 201.1(h)(2). No advertising copy is quoted in the letter at all, and nothing in it concerns sterility, potency or contamination. It is disclosed here, dated, and left to speak for itself.
What is not published
No pharmacy is named — so neither the 503a nor the 503b claim can be checked, and there is nobody to ask for a certificate of analysis, which is not published either. There is a quality section describing sterility and endotoxin screening to USP <797> and USP <85>, which names the standards being worked to; it is a description of a process, not a result you can read.
Where the visit stops
The signup asks for an email, then demands a password-protected account on its second screen — before any medical question and before any price is confirmed. This walk stopped there.
Questions
Frequently asked questions
Is Alan Health's compounded GLP-1 FDA-approved?
No, and Alan says so. Its compounded product page reads "Compounded medications are not FDA-approved; results vary." Compounded preparations are made to a prescription by a state-licensed pharmacy and are not reviewed by FDA for safety, efficacy or quality. Alan also sells four drugs that are approved — Wegovy, Zepbound, Ozempic and Mounjaro — on the same grid, each with an "FDA Approved" badge, and every use of the phrase on those pages belongs to one of them.
Does the trial evidence apply to what Alan sells?
Not directly. The phase 3 trials tested the branded, approved products. A compounded preparation is a different article — potentially the same molecule, but not the product that was studied and not reviewed for how it was made. Here the gap is wider than usual for a specific reason Alan states in a footnote: its "Compounded Semaglutide may include B6, B12, Glycine, and NAD+", so it is a combination preparation, given at a "personalized" dose no registered trial has run. Alan makes no efficacy claim for it, which is the right answer, but a reader arriving with the trial numbers in mind should know those numbers were measured on something else.
Does Alan Health have an FDA warning letter?
Yes — 721814, issued February 20, 2026, and still open. It quotes no advertising copy; its single finding is that the pictured product labels carried Alan's name, implying Alan manufactures the drugs. It makes no allegation about sterility, potency or contamination, and FDA has published no close-out letter. A letter is disclosed here and dated; it is not treated as a verdict on the medication.
Compare
Others selling what Alan Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Alan Health is on
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Alan Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.